Avalon Globocare (Avalon Globocare) Notes Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Avalon Globocare Notes Receivable?

Avalon Globocare's Notes Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Avalon Globocare Notes Receivable Historical Data

The historical data trend for Avalon Globocare's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalon Globocare Notes Receivable Chart

Avalon Globocare Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Notes Receivable

Get a 7-Day Free Trial

Avalon Globocare Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Avalon Globocare Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Avalon Globocare Notes Receivable Related Terms

Thank you for viewing the detailed overview of Avalon Globocare's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalon Globocare (Avalon Globocare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Avalon Globocare Corp (NAS:ALBT) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

4400 Route 9 South, Suite 3100, Freehold, NJ, USA, 07728

Website

https://www.avalon-globocare.com

Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. It has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

Executives

Lourdes Felix	director	15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
W J Tauzin	director	901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Wenzhao Lu	director, 10 percent owner	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Andrew Sanders	director	431 EAST 20TH STREET, NEW YORK NY 10010
Yancen Lu	director	14009 SE 50TH STREET, BELLEVUE WA 98006
Stilley William B. Iii	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Tevi Troy	director	611 SOMERSWORTH WAY, SILVER SPRING MD 20902
Luisa Ingargiola	officer: Chief Financial Officer	4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
David Jin	director, officer: CEO and President	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Yue Charles Li	director	C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9 SOUTH, SUITE 3100, FREEHOLD NJ 07728
Meng Li	director, officer: Chief Operating Officer	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Philip Sukel	director	33 ALPINE DRIVE, MORGANVILLE NJ 07751